Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec 18;22(12):1887-1888.
doi: 10.1093/neuonc/noaa194.

Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?

Tejpal Gupta  1   2 , Abhishek Chatterjee  1   2 , Vijay Patil  3
Affiliations
Comment

Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?

Tejpal Gupta et al. Neuro Oncol. .
No abstract available

Keywords: adjuvant; extended; glioblastoma; survival; temozolomide.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Biomarker-based Optimization of Adjuvant Therapy (BOAT) study schema for newly diagnosed glioblastoma. Note the first randomization (2:1 ratio) for patients with methylated MGMT (stratum 1) into the experimental arm of extended adjuvant TMZ vs 6 cycles of adjuvant TMZ (control arm). Patients in the experimental arm of extended adjuvant TMZ undergo a second randomization (1:1 ratio) into 12 cycles (TMZ-12) vs 24 cycles (TMZ-24). Patients with unmethylated MGMT (stratum 2) are randomized (1:1 ratio) into standard-dose RT/TMZ + 6 cycles of adjuvant TMZ (control arm) versus dose-escalated RT/TMZ + 6 cycles of adjuvant TMZ (experimental arm).
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Balana C, Vaz MA, Sepulveda JM, et al. . A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro Oncol. 2020. (in press). doi: 10.1093/neuonc/noaa107. - DOI - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups ; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. - PubMed
    1. Blumenthal DT, Gorlia T, Gilbert MR, et al. . Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol. 2017;19(8):1119–1126. - PMC - PubMed
    1. Herrlinger U, Tzaridis T, Mack F, et al. ; Neuro-Oncology Working Group of the German Cancer Society Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678–688. - PubMed
    1. Gilbert MR, Wang M, Aldape KD, et al. . Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091. - PMC - PubMed

MeSH terms